{"entity":{"id":"e-edv-d682","kind":"drug","name":"E-EDV-D682","aka":[],"tldr":"E-EDV-D682 is an experimental EDV nanocell (bacterial minicell) drug conjugate from Engeneic Pty in phase 2 trials for pancreatic ductal adenocarcinoma, aimed at EGFR.","summary":"E-EDV-D682 (EDV-D682) is an EDV nanocell (bacterial minicell) drug conjugate developed by Engeneic Pty. Its target is EGFR (the sponsor names EGFR). The sponsor states: E-EDV-D682 packages the chemotherapeutic payload PNU-159682 inside a 400 nm, bacterially derived EnGeneIC EDV nanocell that is targeted to EGFR-expressing cancer cells via a bispecific antibody, delivering the payload directly into tumour cells. ClinicalTrials.gov describes the intervention as: E-EDV-D682 is a product based on the EnGeneIC EDV™ technology. EDVs are bacterially derived nanocells 400 nm in diameter that can be packaged with a range of different chemotherapeutic drugs and specifically targeted to cancer cell receptor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in pancreatic ductal adenocarcinoma. The largest, NCT07049055, plans to enrol 144 participants with primary completion expected 2028-09. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of E-EDV-D682","url":"https://clinicaltrials.gov/search?intr=EDV-D682"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":["engeneic"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07049055"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"EDV-D682","modality":"EDV nanocell (bacterial minicell) drug conjugate","mechanism":"E-EDV-D682 packages the chemotherapeutic payload PNU-159682 inside a 400 nm, bacterially derived EnGeneIC EDV nanocell that is targeted to EGFR-expressing cancer cells via a bispecific antibody, delivering the payload directly into tumour cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/e-edv-d682/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"company":[{"id":"engeneic","kind":"company","name":"EnGeneIC","route":"/companies/engeneic/"}],"trial":[{"id":"nct07049055","kind":"trial","name":"A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer","route":"/trials/nct07049055/"}]}}